News

Iterum Therapeutics Prepares for Earnings Release Insights

Iterum Therapeutics Prepares for Earnings Release Insights

Anticipating the Upcoming Earnings Release for Iterum Therapeutics

Iterum Therapeutics (NASDAQ: ITRM) is gearing up for its quarterly earnings announcement, a key event eagerly awaited by investors. With expectations building in the market, this article delves into the critical aspects investors should consider ahead of the earnings report.

What Analysts Forecast

Analysts predict that Iterum Therapeutics will report an earnings per share (EPS) of $-0.13. This figure is crucial as it reflects the company's performance and gives insights into its potential trajectory moving forward.

The Importance of Guidance

Particularly for new investors, following earnings guidance can be significant. Guidance often becomes a powerful driver of stock valuations, influencing how traders position themselves leading up to and following the announcement.

Previous Earnings Analysis

Looking back at the company's recent performance can shine a light on what might happen next. In the last quarter, Iterum Therapeutics reported an EPS of $-0.10, surpassing estimates by $0.04, which helped boost its share price by 0.13% the following day.

Recent Earnings Performance Summary

Let’s break down Iterum Therapeutics’s performance over the last few quarters:

  • Q1 2025: EPS Estimate: -0.14, Actual: -0.10, Price Change: 0.0%
  • Q4 2024: EPS Estimate: -0.24, Actual: -0.12, Price Change: -4.0%
  • Q3 2024: EPS Estimate: -0.21, Actual: -0.24, Price Change: 1.0%
  • Q2 2024: EPS Estimate: -0.45, Actual: -0.23, Price Change: 1.0%

Current Stock Performance Context

As of early August, shares of Iterum Therapeutics are trading at $0.732, reflecting a significant decline of 37.93% over the past year. Given this downturn, long-term investors may be feeling apprehensive as the company approaches its earnings release.

Looking Forward

With earnings around the corner, there is a palpable sense of anticipation. Investors are hopeful that the company will surpass expectations and provide optimistic guidance for the future.

Frequently Asked Questions

What is the expected EPS for Iterum Therapeutics?

Analysts expect an EPS of $-0.13 for the upcoming quarterly earnings.

When is the next earnings announcement for Iterum Therapeutics?

The next earnings announcement is set for a future date yet to be specified, but markets remain attentive to the company's actions.

How has Iterum Therapeutics performed in the past quarters?

Recently, Iterum achieved an EPS beat last quarter, reporting an EPS of $-0.10, which was better than expected.

What has been the stock's performance over the past year?

Iterum Therapeutics stock has seen a decline of 37.93% in the last 52 weeks, raising concerns among long-term shareholders.

Why is guidance important in earnings reports?

Guidance is crucial as it often influences investor sentiment and stock prices significantly, prompting traders to make strategic decisions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 5

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading

Top 5 Most Recently Viewed Articles

Great Hearts Introduces Services for Classical Education Support

Updated Category News Views 117

Great Hearts Launches New Support Services for Classical Schools Great Hearts, a leader in K-12 classical education, proudly announces the launch of Great Hearts Services. This new initiative aims to provide extensive instructional and operational support to classical schools throughout the country. The goal is not just to offer help but to partner with educational...

Continue Reading
Funding Boost Elevates Kindred's Home Swapping System

Updated Category News Views 211

Funding Announcement for Kindred In an exciting development, Kindred, a pioneering home swapping platform, has successfully raised $125 million to fuel its expansion. This substantial funding marks a significant step in establishing home swapping as a legitimate option in the travel industry, which has traditionally revolved around hotels and short-term rentals....

Continue Reading
Transforming Public Safety: Real-Time 9-1-1 Integration

Updated Category News Views 71

Revolutionizing Emergency Response with Technology Motorola Solutions (NYSE: MSI) is making significant strides in public safety by integrating real-time 9-1-1 intelligence into law enforcement's crime response systems. By funneling critical 9-1-1 call data directly into real-time crime centers (RTCCs), Motorola Solutions ensures that police can respond faster and more...

Continue Reading
Transformative Storytelling Retreat for Aspiring Leaders

Updated Category News Views 131

Introducing Story Camp™ by GhostRanch Communications GhostRanch Communications is excited to unveil Story Camp™, a retreat specifically designed for emerging leaders looking to enhance their presentation and storytelling skills. This inventive program aims to provide participants with the tools they need to elevate their communication and engage effectively with their...

Continue Reading
Leica's Big Move: What StatLab Means for Investors

Updated Category News Views 36

Leica Biosystems Sets Sights on StatLab There's a fresh chapter brewing in the niche of cancer diagnostics as Leica Biosystems, riding on the shoulders of Danaher, decides it's time to acquire StatLab. Consider this a big shake-up in the anatomic pathology playground. Leica is known for striding through the path of cancer diagnostics with aplomb, while StatLab brings to...

Continue Reading